| Name | Title | Contact Details |
|---|---|---|
Jeff Debrosse |
Chief Technology Officer | Profile |
In a time when humanity needs to rethink the future to sustain life on this planet, we consider responsible business a necessary game changer. That is why we are a company that offers 100% organic cotton products for customers who seek delicious, sustainable goods of premium quality. We want our products to last long enough to be passed on. We create them to be enjoyed and used. And we insist on developing a new, sustainable standard of designed goods. #design #functionality #longlasting #newstandard #BCorp #GOTS #organic #feelgood
Were redefining the essence of classic ownership—vehicles not just restored, but entirely reborn. Our name ‘Velocity mirrors the swift pace at which were transforming the industry, setting a new benchmark for todays modern classic enthusiast.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Acrisure Re is a leading re/insurance intermediary and corporate advisor/broker dealer, offering bespoke and innovative capital, risk, and program solutions. Our expert multi-disciplinary team leverage their combined experience, market data and leading analytics to provide the very best placement and execution strategies. Operating in Bermuda, Florida, Italy, London, Minnesota, New York, North Carolina, Seattle, Toronto and Zurich, our global team of experienced and talented employees are dedicated to driving a sophisticated, tech-enabled future for the (re)insurance industry.
InterWest was founded in 1992 as a result of the merger of three large successful insurance brokerage firms located in Northern California. Our aggressive entrepreneurial and acquisition efforts have extended our footprint into Central California and the San Francisco Bay Area. Our unyielding commitment to reinvesting in our staff, diversified products & services and innovative technology consistently places us among the top performing insurance and consulting brokerages in the country. We offer unparalleled expertise in all lines of property and casualty, workers compensation, employee benefits and personal insurance coverages, as well as a full range of surety products. Although we operate principally in California, we are licensed to write business in all 50 states and staffed to service clients with locations throughout the nation.